Replies to post #386340 on Amarin Corp Plc (AMRN)

[xblkbk]

Amen.

[Monk44]

FFS
Is this really you?

[hayward]

FlyFishingAStocks

I thought you said we were going bankrupt has that changed ?? TIA

Michael

[golf stud]

Well that would be wonderful

I do think these trials will be positive and that the share price responds in a great way in 2023

Hope I/we are correct

[FlyFishingStocks]

A few publications that should make the future bright for Vascepa

First, the adverse Covid effect on the brain:
Alzheimers like changes found in Covid Patients

Combined with this:
Eicosapentaenoic acid increases the degradation of amyloid-ß

Omega-3 polyunsaturated fatty acids (PUFAs) have been proposed to be highly beneficial in Alzheimer's disease (AD). AD pathology is closely linked to an overproduction and accumulation of amyloid-ß (Aß) peptides as extracellular senile plaques in the brain. Total Aß levels are not only dependent on its production by proteolytic processing of the amyloid precursor protein (APP), but also on Aß-clearance mechanisms, including Aß-degrading enzymes. Here we show that the omega-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) increase Aß-degradation by affecting insulin-degrading enzyme (IDE), the major Aß-degrading enzyme secreted into the extracellular space of neuronal and microglial cells. The identification of the molecular mechanisms revealed that EPA directly increases IDE enzyme activity and elevates gene expression of IDE. DHA also directly stimulates IDE enzyme activity and affects IDE sorting by increasing exosome release of IDE, resulting in enhanced Aß-degradation in the extracellular milieu. Apart from the known positive effect of DHA in reducing Aß production, EPA and DHA might ameliorate AD pathology by increasing Aß turnover.

= $$$$$$$$$$$$$$$$$$$$$$$$$$